AbbVie Inc. (ABBV)

68.19
0.13 0.19
NYSE : Health Technology
Prev Close 68.32
Open 68.57
Day Low/High 68.10 / 68.95
52 Wk Low/High 65.06 / 100.23
Volume 3.15M
Avg Volume 8.65M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 102.24B
EPS 3.70
P/E Ratio 19.32
Div & Yield 4.28 (5.78%)
13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

Blue Chip stocks are the way to go right now. Here are several key names worth considering.

Amazon Could Rise Another 15% From Here: Market Recon

Amazon Could Rise Another 15% From Here: Market Recon

This stock is still going wild after earnings.

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

AbbVie Becomes #84 Most Shorted S&P 500 Component, Replacing XL Group

AbbVie Becomes #84 Most Shorted S&P 500 Component, Replacing XL Group

The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

10 Large-Cap Stocks With At Least 40% Upside Potential

10 Large-Cap Stocks With At Least 40% Upside Potential

On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 06/15/2018 settlement date, and AbbVie Inc is the #146 most shorted of the S&P 500 components, based on 4.35 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Galapagos' new cystic fibrosis drug trial results were weaker than expected.

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

The Largest U.S. Cannabis Company Finds a Home on a Canadian Exchange

The Largest U.S. Cannabis Company Finds a Home on a Canadian Exchange

MedMen is now selling shares on the Canadian Securities Exchange. Here's why it still isn't possible for the $1.65 billion company to list in its home country.

AbbVie Becomes #233 Most Shorted S&P 500 Component, Replacing Mettler-Toledo International

The most recent short interest data has been released for the 05/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

Amazon and Bank of America Are 2 of 16 Stocks Poised to Change Direction

These names are displaying signs of either bullish or bearish reversal patterns over the past week.

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom

The legal cannabis industry could be worth $24 billion by 2025. Are you willing to pass that up?

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

With Nothing to Buy, Everyone Sells: Cramer's 'Mad Money' Recap (Thur 3/22/18)

Jim Cramer calls it a tsunami of selling. Not one sector of the stock market got a break in Thursday's tariff-inspired decline.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

AbbVie's Cancer Drug Setback Provides Buying Opportunity

AbbVie's Cancer Drug Setback Provides Buying Opportunity

The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.

TheStreet Quant Rating: B- (Buy)